WatchGov

119th Congress

H.R. 5160

Stem Cell Therapeutic and Research Reauthorization Act of 2025

  1. Introduced
  2. In committee
  3. Passed House
  4. Passed Senate
  5. To President
  6. Became law
Sponsor
Christopher H. Smith(R-NJ)
Introduced
Sep 4, 2025
Policy area
Health
Committees
House Committee on Energy and Commerce
Official text
Placed on Calendar Senate · Congress.gov page

Cosponsors (21)

Original cosponsors (5)

Added later (16)

Summary

Summary by the Congressional Research Service· describes the “Reported to House” version

Stem Cell Therapeutic and Research Reauthorization Act of 2025 This bill reauthorizes through FY2031 and revises programs that help patients receive transplants of bone marrow or umbilical cord blood from biologically unrelated donors. These programs are administered by the Health Resources and Services Administration (HRSA). The bill reauthorizes the C.W. Bill Young Cell Transplantation Program. This program supports transplantation of bone marrow and cord blood by increasing the quantities of donations, providing processes for matching and distributing donated materials to patients, and providing related information and research. Also, the bill reauthorizes and revises the National Cord Blood Inventory program, through which HRSA contracts with qualified cord blood banks to collect and maintain a supply of high-quality units for transplantation through the C.W. Bill Young Cell Transplantation Program. The bill amends the inventory program by (1) changing the inventory goal from 150,000 units to a sufficient supply as determined by HRSA, (2) requiring HRSA to manage the size and composition of the inventory to maximize clinical utility and efficiency, and (3) defining high quality cord blood unit to mean a unit meeting current industry standards and the requirements of the Food and Drug Administration.

Roll-call votes

No recorded votes on this bill.

Actions